Epclusa 150 mg-37.5 mg and 200 mg-50 mg coated granules in sachet
*Company:
Gilead Sciences LtdStatus:
No Recent UpdateLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 21 August 2023
File name
Epclusa 150mg-37.5 mg and 200mg-50 mg coated granules in sachet IE&XI PIL (August 2023).pdf
Reasons for updating
- Change to other sources of information section
Updated on 11 May 2023
File name
Epclusa 150 mg-37.5 mg and 200 mg-50 mg coated granules in sachet IE-XI SmPC (April 2023).pdf
Reasons for updating
- Change to section 6.3 - Shelf life
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 11 May 2023
File name
Epclusa 150 mg-37.5 mg and 200 mg-50 mg coated granules in sachet IE-XI SmPC (April 2023).pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 11 May 2023
File name
Epclusa 150 mg-37.5 mg and 200 mg-50 mg coated granules in sachet IE-XI SmPC (April 2023).pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 04 November 2022
File name
Epclusa 150 mg-37.5 mg and 200 mg-50 mg coated granules in sachet IE-XI SmPC (May 2022).pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 04 November 2022
File name
Epclusa 150 mg-37.5 mg and 200 mg-50 mg coated granules in sachet IE-XI PIL (May 2022).pdf
Reasons for updating
- New PIL for new product
Gilead Sciences Ltd
Address:
280 High Holborn, London, WC1V 7EE, UKMedical Information E-mail:
ukmed.info@gilead.comTelephone:
+44 (0)203 681 4500Medical Information Direct Line:
+353 214 825 999 , 08000 113 700 (UK)Customer Care direct line:
+44 (0)203 681 4681